BACKGROUND: Ovarian function suppression (OFS) significantly downregulates the concentration of plasma @entity172 . However, it is unclear whether it offers any survival benefits if combined with adjuvant @entity440 treatment in premenopausal @entity1 . This meta-analysis was designed to assess data from previous studies involving adjuvant @entity440 treatment plus OFS in @entity0 . METHODS: Electronic literature databases (PubMed, Embase, the Web of Science, and the Cochrane Library) were searched for relevant randomized controlled trials published prior to February 1, 2015. Only randomized controlled trials that compared @entity440 alone with @entity440 plus OFS for premenopausal @entity1 with @entity0 were selected. The evaluated endpoints were disease-free survival and overall survival. RESULTS: Four randomized controlled trials comprising 6,279 @entity1 (OFS combination, n=3,133; @entity440 alone, n=3,146) were included in the meta-analysis. There was no significant improvement in disease-free survival or overall survival with addition of OFS in either the whole population or the hormone receptor-positive subgroup. The risk of distant recurrence was not reduced with the addition of OFS in the whole population. A subgroup analysis showed that addition of OFS significantly improved overall survival in @entity1 who were administered chemotherapy. CONCLUSION: Based on the available studies, concurrent administration of OFS and adjuvant @entity440 treatment for premenopausal @entity1 with @entity0 has no effect on prolonging disease-free survival and overall survival, excluding @entity1 who were administered chemotherapy. It should not be widely recommended, except perhaps for @entity1 who were @entity5282 positive and who were also administered adjuvant chemotherapy.

@entity440 with ovarian function suppression versus XXXX alone as an adjuvant treatment for @entity0 : a meta-analysis of published randomized controlled trials.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'premenopausal breast cancer'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity5282 :: ('3164', 'Gene') :: ['hormone-receptor']
@entity440 :: (MESH:D013629,Chemical) :: ['tamoxifen']
